-
Mashup Score: 4BridgeBio wins FDA approval for heart disease drug - 3 hour(s) ago
The FDA approved a new medicine from BridgeBio for patients with ATTR-CM, a progressive heart disease
Source: www.statnews.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 7BridgeBio wins FDA approval for heart disease drug - 5 hour(s) ago
The FDA approved a new medicine from BridgeBio for patients with ATTR-CM, a progressive heart disease
Source: www.statnews.comCategories: General Medicine News, CardiologistsTweet-
As expected! Who are the optimal candidates for acoramidis therapy? When should it be considered first-line therapy? Does the proposed cost provide value? @MasriAhmadMD https://t.co/kSQzuAsLAG
-
-
Mashup Score: 9Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes | NEJM - 1 month(s) ago
Lipid-lowering therapy with statins reduces the risk of cardiovascular events, but the optimal level of low-density lipoprotein (LDL) cholesterol is unclear. We enrolled 4162 patients who had been …
Source: www.nejm.orgCategories: General Medicine News, CardiologistsTweet-
In this sample of 226 votes, majority, by 2:1, preferred formal inference of B is ‘not noninferior’, although both are correct. Data are actually from PROVE-IT trial that aimed to establish NI of 40mg pravastatin (B) relative to 80mg atorvastatin (A). https://t.co/Y2SAhlVesd https://t.co/vuAWw4yFse
-
-
Mashup Score: 4Atmospheric Rivers Hit West Coast - 1 month(s) ago
From late Dec. 2022 into Jan. 2023, a series of nine “atmospheric rivers” dumped a record amount of rain and mountain snow across the western U.S.
Source: www.nesdis.noaa.govCategories: General Medicine News, CardiologistsTweet-
@drjohnm We call them ‘atmospheric rivers’ in California. We were hit by several in the winter of 2022/2023. https://t.co/2xIqLYhXGU
-
-
Mashup Score: 11
The use of intensive lipid-lowering therapy by means of statin medications is recommended after transient ischemic attack (TIA) and ischemic stroke of atherosclerotic origin. The target level for l…
Source: www.nejm.orgCategories: General Medicine News, CardiologistsTweet-
@ErinMichos @cmhc As slide says, it is a confession! Most of supportive evidence for ‘lower is better’ claim is indirect. Only one treat to target trial that I am aware of, & it had to be stopped early for administrative reasons. Don’t we need more solid evidence? https://t.co/2BF1tNaKBW.
-
-
Mashup Score: 2Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes | NEJM - 2 month(s) ago
The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. We randomly assigned patients with type 2 diabetes, with or wit…
Source: www.nejm.orgCategories: General Medicine News, CardiologistsTweet-
@djc795 @JeremySussman @hswapnil @GrahamAbra @Nephro_Sparks @NephroSeeker @captainchloride @Jwaitz @MarkCanney @manasib33 Not really! Strictly speaking, registry randomized trials don't qualify even though the premise might be similar. EXSCEL trial with exenatide qualifies https://t.co/3DDPZK0cjO
-
-
Mashup Score: 4Evidence Generation for Novel Cardiovascular Devices - 3 month(s) ago
Over the last 50 years, cardiovascular medicine has had a substantial effect on human health through careful and continuous innovation and the application of therapies that have been evaluated in randomized clinical trials,1 including numerous advances in the care of patients with acute myocardial…
Source: jamanetwork.comCategories: General Medicine News, CardiologistsTweet-
@djc795 @drjohnm @mmamas1973 @GreggWStone @rwyeh Let me jog your memory of a more recent proposal you made... https://t.co/Ac6JrbABSP
-
-
Mashup Score: 0He Regulated Medical Devices. His Wife Represented Their Makers. - 3 month(s) ago
Ethics rules barred Dr. Jeffrey E. Shuren from working on matters involving clients of his wife’s law firm. But he did not always step aside.
Source: www.nytimes.comCategories: General Medicine News, CardiologistsTweet-
https://t.co/nmlLLobuXk via @NYTimes @LizzyLaw_ @matthewherper
-
-
Mashup Score: 4Inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease: the ORFAN multicentre, longitudinal cohort study - 4 month(s) ago
The FAI Score captures inflammatory risk beyond the current clinical risk stratification and CCTA interpretation, particularly among patients without obstructive CAD. The AI-Risk integrates this information in a prognostic algorithm, which could be used as an alternative to traditional risk factor-based risk calculators.
Source: www.thelancet.comCategories: General Medicine News, CardiologistsTweet-
@DrDave01 @venkmurthy @drjohnm An important question indeed and clearly an unmet need! Look forward to hearing Venk's take on your Q and the results of the ORFAN study. https://t.co/yNebKlpC1Z
-
-
Mashup Score: 16Reteplase versus Alteplase for Acute Ischemic Stroke | NEJM - 5 month(s) ago
Alteplase is the standard agent used in early reperfusion therapy, but alternative thrombolytic agents are needed. The efficacy and safety of reteplase as compared with alteplase in patients with a…
Source: www.nejm.orgCategories: General Medicine News, CardiologistsTweet-
1/ Reteplase versus Alteplase for Acute Ischemic Stroke (RAISE) PEP: MRS 0-1 (excellent functional recovery) at 90d: 79.5% vs 70.4%, RR 1.13, 1.05–1.21 SEP: MRS 0-2 (good functional recovery): 85.3% vs 79.8%, RR 1.07, 1.02–1.12 MRS 6 (death): 4.7% vs 3.8% https://t.co/JMOGIpmqrg
-
As expected! Who are the optimal candidates for acoramidis therapy? When should it be considered first-line therapy? Does the proposed cost provide value? @MasriAhmadMD https://t.co/kSQzuAsLAG